Michael Niederman is a Respiratory physician affiliated with NewYork–Presbyterian Hospital. OpenAlex indexes 458 publications with 33,004 citations (h-index 81); ClinicalTrials.gov lists 1 registered study matched to this name. By OpenAlex citation count, this profile ranks in the top 5% of Pulmonary Disease profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
425 E 61st St Fl 4
New York, NY 100658722
Telephone
646-962-2333Provider last certified this registry record 27 Jun 2023.
Clinical trials
- Use Of Procalcitonin Level For Guidance of The Treatment of Suspected Community Acquired Pneumonia
Sponsor: Winthrop University Hospital
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GlaxoSmithKline, LLC.Program year20251 payment
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
- Merck Sharp & Dohme LLCProgram year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
61.4%Corticosteroid43.5%Trelegy Ellipta36%Breo Ellipta19%Symbicort14%Fluticasone Propionate12%Budesonide-Formoterol Fumarate8%Arnuity Ellipta7%Dulera5%Part D<11 patientsbeta2-Adrenergic Agonist9%Albuterol Sulfate Hfa100%Part D≥47 patients+ 2 more classes in this area
Anti-infectives
25.2%Macrolide Antimicrobial14.4%Azithromycin100%Part D≥45 patientsPenicillins with extended spectrum3.4%Amoxicillin-Clavulanate Potass100%Part D≥26 patients+ 3 more classes in this area
Metabolism & gastrointestinal
12.3%Corticosteroid9.8%Prednisone100%Part D≥44 patientsProton pump inhibitor2.5%Omeprazole100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia
Intensive Care Medicine
2023 - ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia
European Respiratory Journal
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Kevin Clerkin, MD
NewYork–Presbyterian Hospital
Marc Richmond, MD
NewYork–Presbyterian Hospital
Shayan Dioun, MD
NewYork–Presbyterian Hospital
Manuel Hidalgo Medina, MD
NewYork–Presbyterian Hospital
Fernando Martinez, MD
University of Massachusetts Chan Medical School
David Gozal, MD
Marshall University
Ronald Crystal, MD
Weill Cornell Medicine
Bartolome Celli, MD
Brigham and Women's Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”